Efficacy and safety of Reyanning mixture in patients infected with SARS-CoV-2 Omicron variant: A prospective, open-label, randomized controlled trial

[1]  S. Liangpunsakul,et al.  Traditional Chinese Medicine JingYinGuBiao Formula Therapy Improves the Negative Conversion Rate of SARS-CoV2 in Patients with Mild COVID-19 , 2022, International journal of biological sciences.

[2]  Guoliang Zhang,et al.  Treating patients infected with the SARS-CoV-2 Omicron variant with a traditional Chinese medicine, Shufeng Jiedu capsule. , 2022, Bioscience trends.

[3]  M. Ajelli,et al.  Epidemiological characteristics and transmission dynamics of the outbreak caused by the SARS-CoV-2 Omicron variant in Shanghai, China: a descriptive study , 2022, The Lancet Regional Health - Western Pacific.

[4]  Wenhong Zhang,et al.  Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic , 2022, The Lancet.

[5]  Yuting Sun,et al.  [Analysis of clinical characteristics and prognosis of 4 264 patients with asymptomatic and mild novel coronavirus infections in Shanghai]. , 2022, Zhonghua wei zhong bing ji jiu yi xue.

[6]  H. Brüssow.  COVID‐19: Omicron – the latest, the least virulent, but probably not the last variant of concern of SARS‐CoV‐2 , 2022, Microbial biotechnology.

[7]  Yanming Xie,et al.  [Clinical comprehensive evaluation of Reyanning Mixture in treatment of acute upper respiratory tract infection (heat-toxin attacking lung syndrome)]. , 2022, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica.

[8]  M. Baniecki,et al.  Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 , 2022, The New England journal of medicine.

[9]  D. Fremont,et al.  An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies , 2022, Nature Medicine.

[10]  G. Wei,et al.  Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance , 2022, J. Chem. Inf. Model..

[11]  P. Maes,et al.  Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern , 2021, bioRxiv.

[12]  Jon Cohen.  Omicron sparks a vaccine strategy debate. , 2021, Science.

[13]  J. Skarbinski,et al.  Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients , 2021, The New England journal of medicine.

[14]  J. Butterton,et al.  Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients , 2021, The New England journal of medicine.

[15]  T. Burki.  Omicron variant and booster COVID-19 vaccines , 2021, The Lancet Respiratory Medicine.

[16]  G. Luo,et al.  Omicron variant (B.1.1.529) of SARS‐CoV‐2, a global urgent public health alert! , 2021, Journal of medical virology.

[17]  Yue Liu,et al.  Combination of Hua Shi Bai Du granule (Q-14) and standard care in the treatment of patients with coronavirus disease 2019 (COVID-19): A single-center, open-label, randomized controlled trial , 2021, Phytomedicine.

[18]  Xin-yi Zhang,et al.  Efficacy and safety of Xiyanping injection in the treatment of COVID‐19: A multicenter, prospective, open‐label and randomized controlled trial , 2021, Phytotherapy research : PTR.

[19]  An-ping Yang,et al.  Study of the Mechanism of the Reyanning Mixture Involved in Treating Novel Coronavirus Pneumonia Based on Network Pharmacology , 2020 .

[20]  W. Guan,et al.  Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial , 2020, Phytomedicine.

[21]  Yu-jing Shi,et al.  [Application of Reyanning Mixture in evaluating combining disease with syndrome of human coronavirus pneumonia with pestilence attacking lung syndrome]. , 2020, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica.